Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12345678910111213...15251526»
  • ||||||||||  Journal, IO biomarker:  Trends in the use of immunotherapy to treat soft tissue sarcoma. (Pubmed Central) -  Jun 16, 2024   
    IO use in STS is low but increasing and primarily used in the metastatic setting. Future studies should identify biomarkers of IO response and facilitators for treatment receipt.
  • ||||||||||  Journal:  Deep Learning for Grading Endometrial Cancer. (Pubmed Central) -  Jun 16, 2024   
    The model achieved a weighted average F1-score of 0.91 (95% CI: 0.86-0.95) and an AUC of 0.95 (95% CI: 0.89-0.99) on the internal test, and 0.86 (95% CI: 0.80-0.94) for F1-score and 0.86 (95% CI: 0.75-0.93) for AUC on the external test. Pending further validation, EndoNet has the potential to support pathologists without the need of manual annotations in classifying the grades of gynecologic pathology tumors.
  • ||||||||||  Journal:  Identifying FUS amyotrophic lateral sclerosis disease signatures in patient dermal fibroblasts. (Pubmed Central) -  Jun 16, 2024   
    Interestingly, these scores negatively correlated with age of onset, identified several pre-symptomatic individuals and sporadic ALS (sALS) patients with FUS-like fibroblasts, and quantified "movement" of FUS fALS and "FUS-like" sALS toward health upon FUS ASO treatment. Taken together, these findings provide evidence that non-neuronal patient fibroblasts can be used for rapid, personalized assessment in ALS.
  • ||||||||||  Journal:  Disseminated peritoneal leiomyomatosis mimicking carcinomatosis: A case report. (Pubmed Central) -  Jun 16, 2024   
    Taken together, these findings provide evidence that non-neuronal patient fibroblasts can be used for rapid, personalized assessment in ALS. Awareness of the entity is crucial to avoid misdiagnosis and unnecessary anxiety associated with a presumptive diagnosis of malignancy for a largely benign entity.
  • ||||||||||  ibuprofen / Generic mfg.
    Journal:  Tips for Transient Perivascular Inflammation of the Carotid Artery Syndrome. (Pubmed Central) -  Jun 16, 2024   
    The patient had elevated inflammatory markers and was treated clinically for carotidynia with ibuprofen, evaluated by vascular surgery, and discharged home...It is important to be familiar with this diagnosis because treatment is focused on symptomatic relief without the need for invasive procedures. Our goal was to increase awareness of this uncommon diagnosis to improve patient care by preventing unnecessary invasive procedures and aid in timely and accurate diagnosis.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Chitosan-copper microparticles as doxorubicin microcarriers for bone tumor therapy. (Pubmed Central) -  Jun 16, 2024   
    Biological assays indicated mild toxicity of CHT-Cu microparticles on the MG-63 osteosarcoma cell line, without affecting the viability of human mesenchymal stem cells (hMSCs). The DOX@CHT-Cu microparticles at concentration of 0.5 mg mL-1 showed selective toxicity toward MG-63 cells.
  • ||||||||||  Journal:  An Unusual Parotid Mass in a 14-Year-Old Female. (Pubmed Central) -  Jun 15, 2024   
    The DOX@CHT-Cu microparticles at concentration of 0.5 mg mL-1 showed selective toxicity toward MG-63 cells. No abstract available
  • ||||||||||  Journal:  Cytological diagnosis of follicular dendritic cell sarcoma with a unique pattern of D2-40 immunoexpression. (Pubmed Central) -  Jun 15, 2024   
    In addition, D2-40 is reported to be highly sensitive for FDCS with a strong membranous pattern of expression. In this study, we present the cytological diagnosis of a case of FDCS in retroperitoneal lymph nodes with an emphasis on a unique staining pattern of D2-40 which showed a strong nuclear pattern in tumor cells comparable to the membranous pattern of D2-40 on the control tissue and other surgical cases of FDCS in our comparative study.
  • ||||||||||  Journal, Biopsy:  Rapid, equipment-free extraction of DNA from skin biopsies for point-of-care diagnostics. (Pubmed Central) -  Jun 15, 2024   
    Furthermore, the yields achieved via ColdSHOT were robust to sample storage in phosphate-buffered saline (PBS) or Tris-EDTA (TE) buffer prior to DNA extraction, and the DNA sample was stable after extraction. The results presented in this study indicate that the ColdSHOT DNA extraction could be implemented to simplify and accelerate the LAMP-based diagnosis of Kaposi's sarcoma using submillimeter biopsy samples.
  • ||||||||||  Biomarker, Journal, Tumor microenvironment, IO biomarker:  PDE1B, a potential biomarker associated with tumor microenvironment and clinical prognostic significance in osteosarcoma. (Pubmed Central) -  Jun 15, 2024   
    Moreover, PDE1B was found to be markedly associated with immunity (all P?<?0.05), and the TIDE algorithm further shed light on that patients with high-PDE1B expression would have a better immune response to immunotherapies than those with low-PDE1B expression, suggesting that the PDE1B gene could prevent immune escape from osteosarcoma. The PDE1B gene was found to be a tumor suppressor gene in osteosarcoma, and its high expression was related to a better OS prognosis, suppressing immune escape from osteosarcoma.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair. (Pubmed Central) -  Jun 15, 2024   
    Subsequently, our findings indicated that EYA4 could directly interact with histone H2AX to activate the DDR pathway. Taken together, our observations indicated that EYA4 may serve as a target molecule for reversing drug resistance in OS patients.
  • ||||||||||  Review, Journal:  Paraneoplastic Leukemoid reaction in soft tissue sarcoma: A case report and literature review. (Pubmed Central) -  Jun 15, 2024   
    It highlights the necessity of a multidisciplinary approach for accurate diagnosis and effective treatment. The case contributes to the surgical literature by detailing the diagnostic process and therapeutic interventions in managing such complex presentations, thereby providing key "take-away" lessons on the importance of considering PLRs in the differential diagnosis of leukocytosis in patients with malignancies.
  • ||||||||||  Review, Journal:  Survivin (BIRC5): Implications in cancer therapy. (Pubmed Central) -  Jun 15, 2024   
    We will delve into the modulation of Survivin by cancer pro-survival cell signaling, the association between SNPs and tumorigenesis, and its regulation by miRNAs. Finally, we will compare cell growth, clonogenic capacity, and apoptosis, along with different strategies for Survivin inhibition, including gene expression and protein activity modulation.
  • ||||||||||  Retrospective data, Journal:  Is p53 immunohistochemistry alone useful for delineating adjuvant endometrial treatment in low-middle-income countries? (Pubmed Central) -  Jun 15, 2024   
    This retrospective analysis corroborates the finding of worse outcomes for p53 aberrant tumours in stage I/II EC and the benefit of more aggressive adjuvant treatment (systemic therapy and radiotherapy). Although not ideal as a sole molecular marker, p53 immunohistochemistry could complement the classical anatomopathological features and be part of the decision-making process with patients in LMIC.
  • ||||||||||  Retrospective data, Journal:  Clinicopathological and molecular genetic analysis of 13 cases of primary retroperitoneal Ewing sarcoma. (Pubmed Central) -  Jun 15, 2024   
    RES is an aggressive, high-grade tumor, prone to multiple recurrences and metastases, with distinctive morphologic, immunohistochemical, and molecular genetic features. ERCC4 splicing mutation, which is a novel pathogenic variant discovered for the first time, with possible significance for understanding the disease, as well as the development of targeted drugs.
  • ||||||||||  Journal:  Cadherin-11 contributes to the heterogenous and dynamic Wnt-Wnt-?-catenin pathway activation in Ewing sarcoma. (Pubmed Central) -  Jun 14, 2024   
    Knockdown of CDH11 leads to delayed and decreased response to exogenous Wnt ligand stimulation, and ultimately decreased metastatic propensity. Our findings strongly indicate that CDH11 is a key component of regulating Wnt//?-Catenin signaling heterogeneity within Ewing sarcoma tumors, and is a promising molecular target to alter Wnt//?-Catenin signaling in Ewing sarcoma patients.
  • ||||||||||  Journal, CAR T-Cell Therapy:  Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen-induced exhaustion. (Pubmed Central) -  Jun 14, 2024   
    On the other hand, the gene signature of KO CD70-specific nanoCAR T cells overlapped with the gene signature of CAR T-cell infusion products that led to complete responses in chronic lymphatic leukemia patients. Our data show that CARs targeting endogenous T-cell antigens negatively affect CAR T-cell functionality by inducing an exhausted state, which can be overcome by knocking out the specific target.
  • ||||||||||  Review, Journal:  Interventional oncology in children: Where are we now? (Pubmed Central) -  Jun 14, 2024   
    This review outlines the present indications for interventional radiology in paediatric cancer, from biopsy to supportive care, including complication management. It emphasises the role of locoregional approaches, and explores the status of common paediatric oncological diseases, highlighting areas where IO has made progress identifying potential opportunities for future advancements in this evolving field.
  • ||||||||||  Journal:  2?D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells. (Pubmed Central) -  Jun 14, 2024   
    It was concluded that 2?D08 exerts antitumor effects in Ut?LMS cells by modulating multiple signaling pathways and that 2?D08 may be a promising candidate for the treatment of human Ut?LMS. The present study expanded and developed knowledge regarding Ut?LMS management and indicated that 2?D08 represents a notable finding in the exploration of fresh treatment options for such cancerous tumors.
  • ||||||||||  Journal, IO biomarker:  Identifying MAGE-A4-positive tumors for TCR T (Pubmed Central) -  Jun 14, 2024   
    P=N/A, P2
    The covariates were generally not associated with MAGE-A4 expression, except for patient age in ovarian cancer and histology in non-small cell lung cancer. This report shows the eligibility rate from biomarker screening for TCR T
  • ||||||||||  Journal:  An infrequent case of retroperitoneal synovial sarcoma. (Pubmed Central) -  Jun 14, 2024   
    Consequently, the 5-year survival rate is only 20%-29%. This report introduces a case of RSS in a 19-year-old male patient with imaging characteristics on computed tomography (CT) and magnetic resonance (MR).
  • ||||||||||  Retrospective data, Journal:  Fertility preservation in male adolescents with cancer (2011-2020): A retrospective study in China. (Pubmed Central) -  Jun 14, 2024   
    The majority of RMPNST patients have a good prognosis after surgery, and the establishment of high-low group is helpful for clinical decision-making. The aim of this study is to raise awareness of fertility preservation in male adolescents with cancer, to advocate for fertility preservation prior to gonadotoxic therapy or other procedures that may impair future fertility, and to improve the fertility status of future patients.